Yi Lin, MD, PhD, explains the potential impact the approval of idecabtagene vicleucel could bring to the multiple myeloma field.
Yi Lin, MD, PhD, an assistant professor for Oncology and Medicine at the Mayo Clinic, explains the potential impact the approval of idecabtagene vicleucel (Ide-cel) could bring to the multiple myeloma field.
Based on the data ide-cel showed in the phase 3 KarMMa study (NCT03361748), Lin says that it is likely that ide-cel will be granted approval by the FDA in 2021 for patients who have had at least 3 lines of prior therapy and have been exposed to the currently approved 3 main backbones of treatment. The 3 backbone of treatments include a protosome inhibitor, an immunomodulatory agent, and a CD38 antibody. The exciting part of this, Lin says, is that ide-cel may become the first FDA-approved chimeric antigen receptor T-cell therapy for multiple myeloma.
Lin also states that although the ide-cel indication may be for previously-treated patients, there is likely more benefit for these patients if they receive treatment earlier on in their disease course.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More